Levodopa/carbidopa in Parkinson’s disease

Adjunct to levodopa/carbidopa in Parkinson s disease longer acting than bromocriptine... 

Pergolide (Permax) D1 and D2 agonist. More potent than bromocriptine. Adjunct to levodopa/carbidopa in Parkinson s Disease patients. Dyskinesia, nausea, rhinitis, constipation, dizziness, hallucinations, somnolence... 

Lcibcrman, A., Goodgold, A.. Jonas, S. and Leibowitz, M. (1975) Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson s disease. Neurology, 25, 911. 

Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson s disease a multicenter 5-year study. The CR First Study Group. Eur Neurol 1997 37 23-27. 

Dosage of carbidopa-levodopa can at times be reduced by f 0-30% after 2-3 days of adminisfering selegiline 5-f 0 mg/day in Parkinson s disease... 

Parkinson s disease is caused by the oxidative stress-induced loss of dopaminergic neurons and can be effectively treated with levo-dopa in combination with dopa decarboxylase inhibitors such as carbidopa or catechoi-0-methyltransferase inhibitors such as tolca-pone. Levodopa is well known to increase the life spans of patients with Parkinson s disease. It may do this by enhancing brain dopamine levels and inhibiting tyrosine hydroxylase, which produces oxygen radicals. Several dopamine receptor agonists are available for use in Parkinson s disease and are extensively used in patients suffering from the adverse effects of levodopa. Anticholinergics such as trihexyphenidyl are also used in Parkinson s disease. 

Nelson MV, Berchou RC, LeWitt PA, et al. Pharmacodynamic modeling of concentration-effect relationships after controlled release carbidopa/ levodopa (Sinemet CR4) in Parkinson s disease. Neurology 1990 40 70-74. 

Carbidopa (Lodosyn) Diminishes decarboxylation of l-dopa in periphery tissues. Improve effect of l-dopa, decrease required dose of l-dopa by about 75%, i nausea and vomiting. Adjunct in Parkinson s disease. Does not alleviate most side effects caused by levodopa. Has no known toxicities when administered alone. 

The main clinical use of COMT inhibitors is as adjunct (or additional adjunct) in the therapy of Parkinson s disease. The standard therapy of Parkinson s disease is oral L-dopa (as a drug levodopa) given with a dopa decarboxylase (DDC) inhibitor (e.g. carbidopa and benserazide), which does not reach the brain. When the peripheral DDC is inhibited, the concentration of 3-O-methyldopa (3-OMD), a product of COMT, in plasma is many times that of L-dopa. Since the half-life of 3-OMD is about 15 h, compared to about 1 h for L-dopa, the concentration of 3-OMD remains particularly high during chronic therapy, especially if new slow release L-dopa preparations are used. A triple therapy (L-dopa plus DDC inhibitor plus COMT-inhibitor) will... 

Levodopa is a chemical formulation found in plants and animals that is converted into dopamine by nerve cells in the brain. Levodopa does cross die blood-brain barrier, and a small amount is dien converted to dopamine. This allows the drug to have a pharmacologic effect in patients witii Parkinson s disease (Pig. 29-1). Combining levodopa witii another drug (carbidopa) causes more levodopa to reach die brain. When more levodopa is available, the dosage of levodopa may be reduced. Carbidopa has no effect when given alone. Sinemet is a combination of carbidopa and levodopa and is available in several combinations (eg, Sinemet 10/100 has 10 mg of carbidopa and 100 mg of levodopa Sinemet CR is a time-released version of die combined drugs). 

Dopamine-Boosting Medications. Levodopa/carbidopa (Sinemet), bromocriptine (Parlodel), pramipexole (Mirapex), and ropinirole (Requip) increase dopamine nenrotransmission in the brain by one or another mechanism. These medications do not reliably induce sleep, and in some patients are activating. They are certainly not true sedative-hypnotics. They are most often used by neurologists to treat Parkinson s disease. 

Parkinson s disease As an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson s disease who experience the signs and symptoms of end-of-dose wearing-off. The effectiveness of entacapone has not been systematically evaluated in patients with idiopathic Parkinson s disease who do not experience end-of-dose wearing-off. ... 

Parkinson s disease Adjunct in the management of parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. 

Levodopa, the metabolic precursor of dopamine, is the most effective agent in the treatment of Parkinson s disease but not for drug-induced Parkinsonism. Oral levodopa is absorbed by an active transport system for aromatic amino acids. Levodopa has a short elimination half-life of 1-3 hours. Transport over the blood-brain barrier is also mediated by an active process. In the brain levodopa is converted to dopamine by decarboxylation and both its therapeutic and adverse effects are mediated by dopamine. Either re-uptake of dopamine takes place or it is metabolized, mainly by monoamine oxidases. The isoenzyme monoamine oxidase B (MAO-B) is responsible for the majority of oxidative metabolism of dopamine in the striatum. As considerable peripheral conversion of levodopa to dopamine takes place large doses of the drug are needed if given alone. Such doses are associated with a high rate of side effects, especially nausea and vomiting but also cardiovascular adverse reactions. Peripheral dopa decarboxylase inhibitors like carbidopa or benserazide do not cross the blood-brain barrier and therefore only interfere with levodopa decarboxylation in the periphery. The combined treatment with levodopa with a peripheral decarboxylase inhibitor considerably decreases oral levodopa doses. However it should be realized that neuropsychiatric complications are not prevented by decarboxylase inhibitors as even with lower doses relatively more levodopa becomes available in the brain. 

Mecfianism of Action Levodopa is converted to dopamine in the basal ganglia thus increasing dopamine concentration in brain and inhibiting hyperactive cholinergic activity. Carbidopa prevents peripheral breakdown of levodopa, allowing more levo-dopa to be available for transport into the brain. Therapeutic Effect Reduces tremor and other symptoms of Parkinson s disease. 

Geriatric Considerations - Summary Levodopa is a precursor to dopamine and is converted to dopamine in the CNS. Carbidopa decreases peripheral conversion and increases CNS concentrations of levodopa. While sustained-release forms may be helpful in decreasing the wearing-off of levodopa effectiveness, there maybe little advantage over immediate-release preparations. This drug combination is often used as initial therapy for Parkinson s disease. 

Adjunctive treatment of Parkinson s disease PO Initially, 100-200 mg 3 times a day concomitantly with each dose of carbidopa and levodopa. Maximum 600 mg/day Dosage in hepatic impairment Patients with moderate to severe cirrhosis should not receive more than 200 mg tolcapone 3 times a day... 

Since Parkinson s disease arises from a deficiency of DA in the brain, the logical treatment is to replace the DA. Unfortunately, dopamine replacement therapy cannot be done with DA because it does not cross the blood-brain barrier. However, high doses (3-8 g/day, orally) of L(-)-DOPA (levodopa), a prodrug of DA, have a remarkable effect on the akinesia and rigidity. The side effects of such enormous doses are numerous and unpleasant, consisting initially of nausea and vomiting and later of uncontrolled movements (limb dyskinesias). The simultaneous administration of carbidopa (4.75) or benserazide (4.76)—peripheral DOPA decarboxylase inhibitors—allows the administration of smaller doses, and also prevents the metabolic formation of peripheral DA, which can act as an emetic at the vomiting center in the brainstem where the blood-brain barrier is not very effective and can be penetrated by peripheral DA. 

Later, the disease does not respond to the drug and doses are required to be given in combination with carbidopa. Levodopa is effective in relieving bradykinesia and other disorderly voluntary movements. Parkinson s disease is not a hereditary disease. Drugs such as levodopa, carbidopa, benserazide, bromocriptine, pergolide, selegiline, and amantadine are used as therapeutic agents.61... 

Therapeutic uses Levodopa in combination with carbidopa is a potent and efficacious drug regimen currently available to treat Parkinson s disease. In approximately two thirds of patients with Parkinson s disease, levodopa/carbidopa treatment substantially reduces the severity of the disease for the first few years of treatment. Patients then typically experience a decline in response during the third to fifth year of therapy. 

The following are new, non-ergot dopamine agonists that have been approved for the treatment of Parkinson s disease. Pramipexole and ropinirole are effective as first-line and adjunctive therapy, whereas tolcapone should only be used as an adjunct in patients on levodopa/carbidopa. 

CENTRALLY ACTING ANTI HYPERTENSIVES LEVODOPA 1. Clonidine may oppose the effect of levodopa/ carbidopa 2. Methyldopa may 1 levodopa requirements, although there are case reports of deteriorating dyskinesias in some patients 1. Uncertain at present 2. Uncertain at present 1. Watch for deterioration in control of symptoms of Parkinson s disease 2. Levodopa needs may 1 in cases of worsening Parkinson s control, use an alternative antihypertensive... 

LEVODOPA, SELEGILINE, POSSIBLY RASAGILINE, ENTACAPONE, TOLCAPONE MAOIs Risk of adrenergic syndrome -hypertension, hyperthermia, arrhythmias - and dopaminergic effects with selegiline Levodopa and related drugs are precursors of dopamine. Levodopa is predominantly metabolized to dopamine, and a smaller proportion is converted to epinephrine and norepinephrine. Effects are due to inhibition of MAOI, which breaks down dopamine and sympathomimetics Avoid concurrent use. Onset may be 6-24 hours after ingestion. Carbidopa and benserazide, which inhibit dopa decarboxylase that converts L-dopa to dopamine, is considered to minimize this interaction. However, MAOIs should not be used in patients with Parkinson s disease on treatment with levodopa. Imipramine and amitriptyline are considered safer by some clinicians... 

About 4 hours after a 65-year-old man with Parkinson s disease took talipexole hydrochloride 0.8 mg, he acutely developed sleepiness, delusion, akinesia, and faintness associated with hypotension and sinus bradycardia. A similar episode occurred when he took talipexole hydrochloride 1.2 mg/day in combination with co-careldopa (levodopa 200 mg/day plus carbidopa 20 mg/day). These symptoms persisted for 12 hours and abated gradually without any specific treatment. 

CD is a 70-year-old man who resides in a nursing home. His PMH is significant for Parkinson s disease and COPD. His medications include carbidopa/levodopa, and amantadine, as well as ipratropium, albuterol, and triamcinolone inhalers. One of the residents is diagnosed with influenza A and all the residents now require prophylaxis for influenza A with rimantadine. Which of the following would be the most appropriate therapy for prevention of influenza A in CD ... 

Adjunctive to levodopa/carbidopa in treatment of Parkinson s disease... 

Carbidopa has no effect when given alone. It is used along with levodopa in the management of Parkinson s disease. When administered orally, levodopa is metabolized substantially in... 

---